179232-29-2

Basic information

• Product Name: Methyl 4-bromo-2-fluorobenzoate
• Synonyms: Methyl 4-bromo-2-fluorobenzoate;4-BROMO-2-FLUOROBENZOIC ACID METHYL ESTER;Fluoro-4-bromobenzoate
• CAS NO: 179232-29-2
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.04
• Product Categories: blocks;Bromides;Carboxes;FluoroCompounds;Aromatic Esters
• Mol File: 179232-29-2.mol

Chemical Properties

• Melting Point: 58-60℃
• Boiling Point: 272.7±25.0℃ (760 Torr)
• Flash Point: 118.7±23.2℃
• Appearance: /
• Density: 1.577±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Methyl 4-bromo-2-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-bromo-2-fluorobenzoate(179232-29-2)
• EPA Substance Registry System: Methyl 4-bromo-2-fluorobenzoate(179232-29-2)

Safety Data

• Hazardous Substances Data: 179232-29-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-bromo-2-fluorobenzoate is used as a reagent for the synthesis of aminopyridyl-based inhibitors. These inhibitors are specifically designed to target Trypanosoma cruzi CYP51, an enzyme crucial for the survival of the parasite responsible for Chagas disease. By inhibiting this enzyme, the compound contributes to the development of anti-Chagas agents, which are essential in combating this life-threatening disease.

InChI:InChI=1/C8H6BrFO2/c1-12-8(11)6-3-2-5(9)4-7(6)10/h2-4H,1H3

Upstream product

• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 151982-51-3 4-bromo-2-fluorobenzoyl chloride 
• 74-88-4 methyl iodide 

Downstream Products

• 797783-34-7 4-(4-chloro-benzoyl)-2-fluoro-benzoic acid methyl ester 
• 863904-21-6 6-bromro-3-hydroxybenzo[b]thiophene-2-carboxylic acid methyl ester 
• 1006876-12-5 methyl 4-acetyl-2-fluorobenzoate 
• 797783-29-0 4-(4-chloro-benzoyl)-2-fluoro-benzoic acid 
• 797783-30-3 3-[4-(4-chloro-benzoyl)-2-fluoro-phenyl]-3-oxo-propionitrile 
• 766556-63-2 2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-benzoic acid methyl ester 
• 749928-52-7 2-(4-bromo-2-fluorophenyl)propan-2-ol 
• 908247-97-2 4-(3,3-Dimethyl-but-1-ynyl)-2-fluoro-benzoic acid methyl ester 
• 175596-01-7 methyl 4-cyano-2-fluorobenzoate 
• 188582-62-9 4-bromo-2-fluorobenzyl alcohol 
• 1075189-78-4 1-(4-bromo-2-fluorophenyl)cyclopentanol 
• 948990-75-8 1-((R)-4-benzoyl-2-methylpiperazin-1-yl)-2-(4-bromo-2-fluorophenyl)ethane-1,2-dione 
• 1226985-36-9 6-bromo-1-methyl-1H-indazol-3-ol 
• 1228782-35-1 methyl 4-bromo-2-(pyridin-4-yloxy)benzoate 

Relevant articles and documents

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

COMPOUNDS AND METHOD OF USE

This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

BTK INHIBITOR

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

HEPATITIS C VIRUS INHIBITORS

A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject.

An improved and practical route for the synthesis of enzalutamide and potential impurities study

An improved and practical synthesis of enzalutamide was accomplished in five steps. Starting from 4-bromo-2-fluoro-benzonic acid, a methyl esterification, Ullmann ligation, methyl esterification, ring closing reaction and final methyl amidation provided the target in 35% total yield with 99.8% purity. Five identified impurities were also synthesized. This efficient and economical procedure avoids the use of highly toxic reagents and multiple recrystallization operations, which is suitable for further industrialization.

XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE

The present invention provides novel compounds having the general formula (I) wherein R1 to R6, X, Y, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds.

TRICYCLIC PIPERIDINE COMPOUNDS

The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acc

INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods o